SHL Telemedicine Receives Buy Rating with $11.00 Price Target
A leading equity research firm provides a double-digit price target for SHL Telemedicine, positioning it as an undervalued opportunity considering its unique technology, expertise and expanding global market.
The equity research report emphasizes SHL Telemedicine's innovative approach and expanding market opportunities, noting that "SHLT is a pure-play in the rapidly expanding
The report also highlights the company’s impressive initial clinical trial results conducted by the Mayo Clinic and Imperial College London, alongside progress and expected growth in the US and
The
Litchfield Hills Research produces FINRA and MIFID II compliant research, and the analyst, Theodore R, O'Neill, has 25+ years of Sell-Side experience with firms such as Wells Fargo, A.G. Edwards, Needham & Co. In addition, he is a two-time winner of the Wall Street Journal Allstar Analyst Awards.
To access the report alongside its full disclaimers and disclosures, please go to: https://bit.ly/shltinitiation
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).
For more information, please visit our website at www.shl-telemedicine.com.
Forward-Looking Statements
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314157429/en/
Fabienne Farner, IRF, Phone : +41 43 244 81 42, farner@irf-reputation.ch
Source: SHL Telemedicine